『Molecular Psychiatry』に掲載された研究では、新しいトレーサーを用いたPET画像診断により、ケタミン投与を受けた治療抵抗性うつ病患者におけるAMPA型グルタミン酸受容体の変化を追跡し、領域特異的な受容体変化が症状改善と関連していることを報告した。
重度うつ病は世界中で障害の主要な原因であり、患者の相当な少数が標準的な抗うつ薬治療に十分に応答しないのです。
AIによるレポート AIによって生成された画像 事実確認済み
A proof-of-concept randomized clinical trial published online May 20, 2026, in JAMA Psychiatry found signals that tocilizumab—an anti-inflammatory drug used for immune-mediated conditions including rheumatoid arthritis—may improve some symptoms in adults with moderate-to-severe depression who had a poor response to antidepressants and evidence of low-grade inflammation.
Researchers at Johns Hopkins Medicine created lab-grown brain organoids from cells of people with Alzheimer’s disease to study how they respond to the antidepressant escitalopram oxalate.
AIによるレポート
Researchers have identified a specific group of neurons in the amygdala that plays a central role in anxiety and social withdrawal. By restoring normal activity in this circuit, they reversed anxiety-related behaviors in mice. The findings point to a potential new target for treating emotional disorders.
A single dose of psilocybin produced lasting shifts in brain activity and possible structural changes detectable up to one month later, according to a new study from researchers at UC San Francisco and Imperial College London.